Rainbow Seed Fund News

  Quethera, a biopharmaceutical company developing therapies for ocular disorders, today presented strong efficacy data at the 2017 Association for Research in Vision and Ophthalmology (ARVO) conference showing its gene therapy QTA020V resulted in a 61% reduction in retinal ganglion cell (RGC) loss in a widely used experimental model of glaucoma. In addition, the company […]

read more

British molecular diagnostics company Cytox plans to make a molecular test for the early-stage diagnosis of Alzheimer’s disease available in the US by year end. The Oxford-based firm is also in discussions with multiple pharmaceutical and biotechnology companies that wish to use its test, which is run on a custom Affymetrix microarray, to select patients […]

read more

— Early-stage venture fund key in bridging gap between UK research and commercialisation — Fund aims to turn UK scientific ‘world’s first’ ambitions into market-leading companies Rainbow Seed Fund, an early-stage venture capital fund focused on promising technologies developed at the UK’s largest publicly-funded research facilities and campuses, today announces that the fund have now […]

read more

1 2 3 9